A Two-part, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of Single Ascending Doses of SAR441121 Including a Pilot Food Evaluation (TDU15302) and its Antimalarial Activity against Plasmodium falciparum Blood Stage Infection (PDY15303) in Healthy Male Subjects.

sanofi-aventis australia ptd ltd0 个研究点目标入组 62 人开始时间: 2018年10月30日最近更新: 2018年11月19日

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 62

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Treatment

入排标准

年龄范围: 18 Years 至 49 Years（—）
性别: Male

入选标准

•Male subjects, between 18 and 49 years of age, inclusive.
•Body weight between 50.0 and 100.0 kg, inclusive, body mass index between 18.0 and 32.0 kg/m2, inclusive.
•Normal vital signs after 5 minutes resting in supine position.
•Normal electrocardiogram parameters after 5 minutes resting in supine position.
•Laboratory parameters within the normal range unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects.
•Male subject, whose partners are of childbearing potential (including pregnant or lactating women), must accept to use, during sexual intercourse, a double contraception method according to the following algorithm: (condom) plus (intrauterine device or hormonal contraceptive) from the inclusion up to 3 months after the last dosing.
•Male subject must agree not to donate sperm from the screening up to 3 months after the last dosing.

排除标准

•Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.
•Presence or history of drug hypersensitivity, or allergic disease diagnosed by an allergist/immunologist and/or treated by a physician for allergy or history of a severe allergic reaction, anaphylaxis or convulsions following any vaccination or infusion, or subjects with a documented food allergy requiring specific medical management
•History or presence of alcohol abuse (alcohol consumption of more than 40g per day) or drug habituation, or any previous usage of an illicit substance.
•Tobacco use of more than 5 cigarettes or equivalent per day, and unable to stop smoking for the duration of the clinical unit confinement.
•Any medication (including St John’s Wort) within 14 days before consenting or within 5 times the elimination half-life or pharmacodynamic half-life of the medication except occasional intakes of ibuprofen at doses up to 1.2g/day or paracetamol at doses up to 2g/day.
•Participation in any investigational product study within the 12 weeks (counted from the last dose taken) prior to Investigational Medicinal Product (IMP) administration.
•Any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 3 months before inclusion.
•Any consumption of grapefruit and Sevilles oranges, etc or their juices within 5 days prior to Investigational Medicinal Product (IMP) administration.
•For the food effect cohort, vegetarian subjects or subjects with lactose intolerance must be excluded.
•History of serious psychiatric condition that may affect participation in the study or preclude compliance with the protocol, including but not limited to past or present psychoses, disorders requiring lithium, a history of attempted or planned suicide, more than one previous episode of major depression, any previous single episode of major depression lasting for or requiring treatment for more than 6 months, or any episode of major depression during the 5 years preceding screening.

研究者

发起方

sanofi-aventis australia ptd ltd

相似试验

进行中（未招募）

1 期

A 2-part study in healthy volunteers to assess the safety and tolerability of the test medicine and explore how it is taken up by the body following single and multiple doses with an optional third part and to compare how the test medicine is taken up by the body when compared to an existing formulation (recipe)Acute Kidney Injury (AKI)Urological and Genital Diseases

ISRCTN16476560nicycive Therapeutics Inc.64

进行中（未招募）

1 期

Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)MedDRA version: 20.0 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10009015 Term: Chronic myeloid leukemia System Organ Class: 100000004864MedDRA version: 20.1 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - Investigations

EUCTR2016-001754-18-ESSun Pharma Advanced Research Company (SPARC) Limited89

进行中（未招募）

1 期

Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)MedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: PTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - Investigations

EUCTR2016-001754-18-ROSun Pharma Advanced Research Company (SPARC) Limited255

进行中（未招募）

1 期

EUCTR2016-001754-18-HUSun Pharma Advanced Research Company (SPARC) Limited255

进行中（未招募）

1 期

EUCTR2016-001754-18-BESun Pharma Advanced Research Company (SPARC) Limited255